Application of immune attacking protection component for inactivated ASFV (African swine fever virus) serving as complex vaccine

An inactivation and multipurpose technology, applied in the direction of virus antigen components, vaccines, veterinary vaccines, etc., can solve the problems of inability to produce immune attack protection effect, unclear virus infection and immune mechanism, complex structure of ASFV, etc., to achieve enhanced immunity Anti-virus protection effect, low biosafety level requirements, and the effect of facilitating large-scale production
CN110302371AActive Publication Date: 2019-10-08ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE
5 Cites 9 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE
Publication Date
2019-10-08

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an application of an immune attacking protection component for an inactivated ASFV (African swine fever virus) serving as a complex vaccine, and relates to an African swine fever gene engineering recombinant living vectored vaccine, subunit vaccine or nucleic acid vaccine immune attacking protection component, namely, an inactivated African swine fever virus or mixture of the inactivated African swine fever virus and adjuvants such as polysaccharides. The inactivated African swine fever virus or the mixture of the inactivated African swine fever virus and the adjuvantssuch as the polysaccharides can improve the immune attacking protection effect of an African swine fever gene engineering recombinant living vectored vaccine, a subunit vaccine or a nucleic acid vaccine, and can realize 100% protection. Besides, the invention further provides the complex vaccine jointly prepared from the immune attacking protection component and the gene engineering recombinant living vectored vaccine, the subunit vaccine or the nucleic acid vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention discloses the use of inactivated ASFV as an immune challenge protection component of a compound vaccine; it relates to an immune challenge protection component of African swine fever genetic engineering recombinant live vector vaccine, subunit vaccine or nucleic acid vaccine, that is, inactivated African swine fever Mixture of virus or inactivated African swine fever virus with adjuvants such as polysaccharides. Inactivated African swine fever virus or the mixture of inactivated African swine fever virus and polysaccharide and other adjuvants can improve the immune challenge protection effect of African swine fever genetically engineered recombinant live vector vaccine, subunit vaccine or nucleic acid vaccine, achieving 100% protection; at the same time, the invention also provides a compound vaccine prepared by combining the immune challenge protection component and the genetically engineered recombinant live vector vaccine or subunit vac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More